KIR3DL1 and neoplasm: While transplants for leukemia are often HLA-matched to reduce the risk of GVHD, haploidentical transplants offer a unique opportunity for mismatching donor NK cells (specifically inhibitory KIR molecules) against HLA molecules present on the tumor, enhancing the GVT effect [154].